Endovascular Aneurysm Repair Devices Market to show steady growth, 2019

Global Endovascular Aneurysm Repair Devices Research Report: By Indication (Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, and Others), by Site (Infrarenal and Pararenal), by Anatomy, and by Products (Percutaneous EVAR and Others)–Forecast Till 2023

Market Scenario

Endovascular aneurysm repair (EVAR) is a collective term for all treatments that are directed to surgically cure an aortic aneurysm located in the patient’s abdomen. Factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the market.

The global endovascular aneurysm repair devices market is currently dominated by many market players. The key players in the market are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, in April 2018, Vascutek Ltd. and Bolton Medical, subsidiaries of Terumo Corporation, have merged into Terumo Aortic. Combining the aortic companies into a single business, Terumo Corporation aims to grow its presence in the aortic and vascular implants market.

It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023.

Key players

·         Cardiatis SA,

·         Cardinal Health,

·         Cook Medical LLC,

·         Endologix, INC.,

·         Jotec GmbH,

·         Medtronic plc,

·         Terumo Corporation,

·         W. L. Gore & Associates, Inc.,

·         BiFlow Medical Ltd,

·         Boston Scientific Corporation,

·         Braile Biomédica,

·         Endoluminal Sciences Pty Ltd,

·         Endospan Ltd.,

·         Getinge AB,

·         Lemaitre Vascular Inc.

Segmentation

The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.

The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.

The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.

The market, on the basis of the site, has been segmented into infrarenal and pararenal.

The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.

The market, on the basis of anatomy, has been segmented into traditional and complex.

The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.

Regional Market Summary

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.

Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.

On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.

Browse more Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

Fibrocystic Breasts Diagnostics and Treatment Market, Segments, Growth and Value Chain 2019

Global Fibrocystic Breasts Diagnostics and Treatment Market: Type (Diagnosis- Mammogram and Breast Biopsy, Treatment- Medications, Fine-Needle Aspiration, Surgical Excision, Oral Contraceptives), End-Users (Hospitals and Others)–Global Forecast Till 2023

More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.

The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.

The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).

Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 

Key Players

Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.

Regional Analysis

In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.

The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.

The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Segmentation

The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.

On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.

On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Global Cardiac Monitoring and Cardiac Rhythm Management Device Market Production, Capacity, Revenue, Price, Gross Margin Analysis and forecast 2019-2023

Global Cardiac Monitoring and Cardiac Rhythm Management Device Market, by Cardiac Device (Pacemaker and Others), by Cardiac Monitoring (Electrocardiogram), by CRM (Defibrillators and Others), by End-User (Hospitals and Others)–Global Forecast Till 2023

Market Scenario

Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also to growth in the market. The global cardiac monitoring and cardiac rhythm management device market is segmented into types of cardiac devices, types of cardiac monitoring devices, types of cardiac rhythm management devices, and end-users. Further, the types of cardiac devices are segmented into pacemaker, biventricular pacemaker, implantable cardioverter defibrillator, and implantable cardiac loop recorder. Based on the types of cardiac monitoring devices the market is further segmented into electrocardiogram (ECG), Holter monitor, event monitor, implantable loop recorder, and cardiac output monitoring devices. Electrocardiogram (ECG) is further sub-segmented into telelectro-cardiogram, wireless ECG, and lead ECG test. Based on types of cardiac rhythm management devices, the market is segmented into defibrillators, pacemakers, and cardiac resynchronization therapy devices. Defibrillations are further sub-segmented into implantable defibrillators and external defibrillators. Based on end-user the market is segmented into hospitals, ambulatory surgical centers, and others.

Global cardiac monitoring and cardiac rhythm management device market is expected to grow during the forecast period (2018 to 2023) at a CAGR ~4%.

Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the cardiac monitoring and cardiac rhythm management device market. Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. The increasing demand for minimally invasive surgeries drives the growth of this market. However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market.

However, the high cost of these devices in developing nations, preference of drugs over devices in the cardiac treatment, and limited insurance coverage options are some of the factors which are hampering the growth of the market.

Key Players

Some of the key players in the global cardiac monitoring and cardiac rhythm management device market are Abiomed, Berlin Hearth, Brotionik SE and Co. KG, Boston Scientific Corporation, Cardiac Science Corporation, General Electric(GE), Hill Rom Services Inc, Jarvik Hearth. Inc, Koninklijke Philips N.V, LivaNova plc, Medtronic plc, Nihon Kohden Corporation, ReliantHeart Inc, Schiller, and Abbott.

Regional Market Summary

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The cardiac monitoring and cardiac rhythm management device market in the Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European cardiac monitoring and cardiac rhythm management device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cardiac monitoring and cardiac rhythm management device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiac monitoring device market in the Middle East and Africa has been segmented into the Middle East and Africa.

The European market is expected to be the second-largest cardiac monitoring device market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of surgeries due to the changing lifestyle is contributing to the growth of the market in this region. Asia-Pacific is expected to be the fastest-growing cardiac monitoring device market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving strong competition in the global cardiac monitoring device market by producing cost-effective products that are high in demand in local as well as global markets. The market in the Middle East and Africa is expected to account for the smallest share in the global cardiac monitoring device market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

In terms of market value, North America will dominate the global cardiac monitoring and cardiac rhythm management device market during the forecast period. The increasing investment by North America in cardiac devices over the last few years has led to the growth of the market in this region. Increasing number of cardiac patients, better healthcare infrastructure, and advanced technology in cardiac monitoring equipment have boosted the cardiac monitoring and cardiac rhythm management device market in North America.

Browse more Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

Digital Wound Measurement Devices Market, Segments, Growth and Value Chain 2019

Global Digital Wound Measurement Devices Market Research Report, by Wound Type (Diabetic Ulcers, Incisional, Traumatic, Chronic), Product (Contact Wounds, Non-Contact Wound Measuring Devices), End-User (Hospital and Clinics) – Global Forecast Till 2023

Market Scenario

The global digital wound measurement devices market is expected to witness a positive growth during the forecast period. Digital wound measurement devices enable monitoring of chronic wounds and deliver the appropriate drug dose to speed up the process of healing. Chronic wounds if not treated on time can lead to severe infections and amputations. Hence, digital wound measurement devices allow delivering tailored treatments after the 2D or 3D assessment of the infection and inflammation. The increasing number of patients suffering from chronic wounds drives the market growth. According to the Intermountain Healthcare (2017), 6.5 million people in the US suffer from chronic wounds. Diabetic wounds are severe, and the process of healing is very long and eventually may lead to amputations. Hence factors such as growing diabetic patients, rising geriatric population, and an increasing number of surgeries are major factors influencing the growth of the market. The emergence of smartphones, rapid use of advanced digital tools, and the advent of telehealth for wound care will also contribute for the market to grow.

However, factors such as, the inability of the device to provide additional information about wounds such as moistness or exudation and high costs of digital devices are expected to restrict the market growth during the forecast period.

Key Players

·         WoundRight Technologies Tissue Analytics

·         Parable Health

·         ARANZ Medical Limited

·         eKare, Inc,

·         KCI,

·         an Acelity Company,

·         WoundMatrix, Inc.,

·         WoundZoom Inc.,

·         Kent Imaging Inc.,

·         WoundRight Technologies, LLC,

·         WoundVision, LLC,

·         Hitachi Healthcare Americas,

·         Smith & Nephew plc.

Segmentation

The global digital wound measurement devices market is segmented on the basis of wound type, product, and end-user. The digital wound measurement devices market, by wound type is sub-segmented into a diabetic ulcer, chronic wounds, burns, incisional, and traumatic. The product segment is sub-segmented into contact wound measuring devices and non-contact wound measuring devices.

On the basis of end-user, the market is segmented into hospitals, clinics, and ambulatory surgical centers.

On the basis of region, the global digital wound measurement devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Market

Asia-Pacific was projected to be the fastest growing region for the global digital wound measurement devices market. Key factors such as rising geriatric population, growing diabetic patient pool, high incidence chronic wounds, and developing healthcare infrastructure drive the market in this region. According to the Asian Diabetes Prevention Initiative, 60% of the world diabetic population is in Asia. This provides favorable backgrounds for the market to grow in Asia.

The digital wound measurement devices market is dominated by North America owing to the rising prevalence of chronic wounds and technological advancements in the healthcare sector.  In June 2018, KCI, an Acelity Company announced the launch of Nurse2Nurse (N2N) Mobile App for wound care nurses. The app allows interactions with clinicians and shares credible insights and information for better patient care.

It is estimated that Europe was the second largest in the global digital wound measurement devices market. The increasing technological advancement and research for wound care along with government support in Europe drive the market growth in this region. The European Wound Management Association will conduct its 29th conference by June 2019 in Gothenburg, Sweden in the presence of several international wound management communities with the common goal of improving the care of wound patients.

The Middle East and Africa holds the least share of the global digital wound measurement devices market due to the presence of stringent government policies and poor economic growth. However, growing awareness and increasing investments by private market players in this region can boost the market growth. 

Browse more Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

Global Uterine Sarcoma Market Production, Capacity, Revenue, Price, Gross Margin Analysis and forecast 2019-2023

Uterine Sarcoma Market research report, type (LMS, undifferentiated sarcoma), diagnosis (sampling & testing, imaging tests), treatment (surgery, radiation therapy, hormone therapy), end users (Hospitals, Research Organization) - global forecast till 2023

Market Scenario:

Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016.

Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.

The market for global uterine sarcoma is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.

Key players

·         Pfizer Inc.

·         Intas Pharmaceuticals Ltd.

·         FMC Corporation

·         Sun Pharmaceutical Industries Ltd.

·         Johnson & Johnson Services, Inc.

·         General Electric Company

·         Koninklijke Philips N.V.

·         Siemens Healthcare Private Limited

Segmentation

The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.

On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.

On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.

On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.

Regional Analysis

Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.

America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.

Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population.  By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.

The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.

Browse more Life Sciences Reports @ https://www.marketresearchfuture.com/categories/life-sciences-market-report

Acoustic Neuroma Market, Segments, Growth and Value Chain 2019

Acoustic Neuroma Market Research Report- By Type (Unilateral, Bilateral) By Diagnosis (Audiometry, Electronystagmography, MRI) By Treatment (Monitoring, Surgery, Radiaotherapy, Supportive Therapy) By Drug Class, By End User– Global Forecast till 2023

The global acoustic neuroma market is expected to grow at a CAGR of approximately 7.6% during the forecast period 2017-2023.

Market Scenario

Acoustic neuromas also known as vestibular schwannomas, usually grows slowly over a period of years. Usually they do not invade the brain, but can push on it as they grow. As the tumor grows, they press the nearby cranial nerves that control the muscles enabling facial expression and sensation. If the tumor becomes large enough to press on the brain stem or cerebellum, it can be deadly. They account for almost 8% of all tumors inside the skull. The prevalence rate is 1 out of every 100,000 individuals per year.

An acoustic neuroma is a non-cancerous (benign) growth that develops on the 8th cranial nerve (vestibulocochlear nerve), it connects the inner ear with the brain and has two different parts. One part is involved in transmitting sound and the other sends balance information to the brain.

Acoustic neuromas are mainly categorized into unilateral and bilateral vestibular schwannomas. Unilateral affect only one ear and bilateral vestibular schwannomas affect both hearing nerves and are usually associated with some genetic disorder. More than half of the affected individuals have inherited the disorder from an affected parent. Several new drugs are launched by the key players which grants various opportunities for the global acoustic neuroma market.

Usually these neuromas are rare. Globally around 1-20 people in every million are diagnosed each year with an acoustic neuroma. Acoustic neuromas account for about 6 cases in every 100 patients with brain tumours. They are more common in middle-aged adults and are rare in children. Furthermore,  these neuromas seem to be more common in women than in men. Acoustic neuromas tend to affect adults aged 30 to 60 and usually have no obvious cause, although a small number of cases are the result of a genetic condition called neurofibromatosis type 2 (NF2).

The gadolinium enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis of vestibular schwannoma yet several examinations may arise suspicion of vestibular schwannomas. According to a patient survey held by the Acoustic Neuroma Association, in 2012, it was reported that after surgical treatment of acoustic neuroma more than 35% patients suffered a headache depending on the type of surgical approach, technique used and the time since surgery.

Top Key Acquisitions

Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.

Some of key the players in the global acoustic neuroma market are GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis AG, Pfizer Inc., and others

Segmentation

The acoustic neuroma is segmented on the basis of type, diagnosis, drug class, treatment, and end-users.

On the basis of type, the market is segmented into unilateral vestibular schwannomas and bilateral vestibular schwannomas.

On the basis of diagnosis, the market is segmented into hearing test (audiometry), electronystagmography, magnetic resonance imaging (MRI), and others.

On the basis of end-user, the market is segmented into hospitals, diagnostic centers, academic and research institutes, and others.

On the basis of drug class, the market is segmented into anticonvulsants, corticosteroids, osmotic diuretics and pain killers.

On the basis of treatment, the market is segmented into monitoring, surgery, radiation therapy, supportive therapy and others. The radiation therapy is sub segmented stereotactic radiotherapy, proton beam therapy. Surgery is sub segmented radiosurgery, craniotomy, and microsurgery removal

Regional Analysis

The global acoustic neuroma market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America is projected to hold the largest share of the global acoustic neuroma market due to presence of huge numbers of key players supporting research and development for developing novel therapies, large base of diagnostic centers and greater emphasis on disease prevention and wellness by governments. Along with that healthcare facilities in the U.S. are gradually moving from treatment to wellness, so the prevention and early detection of disease is critical. Approximately 2,000 to 3,000 cases are diagnosed each year with acoustic neuroma in the United States (6 to 9 per million persons).

The European acoustic neuroma market hold the second largest market as it witness rapid growth. According to NHS U.K, an acoustic neuroma can occasionally return after treatment. This is thought to happen to around 1 in every 20 people who have had surgical removal.

Asia Pacific is expected to be the most promising markets for acoustic neuroma in the near future The Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.

Browse more Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

Intussusception Market to Observe Strong Development by 2019

Intussusception Market Information: By Type (Ileoileal, Ileocolic, Ileo-Ileo-Colic), Diagnosis (Barium Enema, Ultrasound, X-Ray, Computerized Tomography (CT)), Treatment (Surgery, Drugs, Others), End User (Hospitals & Clinics) - Global Forecast till 2023

Market Scenario

According to the National health statistics, intussusception affects about 1 in every 1,900 children in the US. Its incidence is more common in children between one to five months, peaking at four to nine months of age, and then gradually declines at around 18 months. Intussusception affects boys and girls, with a ratio of approximately 3:1.

The global intussusception market is expected to reach USD 6.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.

Intussusception, also called bowel obstruction, is a potentially life-threatening condition caused by folding of one part of the intestine into another part, which causes a blockage in the intestine. The blockage hamper the excretion process. Intussusception is dominant in children of age 2 months-2 years. However, adults may also be affected by the intussusception. It commonly occurs where the small and large intestines meet. Additionally, it can occurs due to various causes such as tumors, inflammation, Meckel's diverticulum, duplication, appendix, hyperplasia of Peyer's patches, intestinal surgery, polyps, tumors, inflammation, etc.

It block the blood supply to intestine and causes tissue death. Tissue death can lead to infection, internal bleeding, tearing, damage to the intestines, and peritonitis. The primary symptoms of intussusception include acute abdominal pain, vomiting, nausea, lethargy, blood or mucus in the stools, constipation, etc. The risk factors for intussusception are age, sex, abnormal intestinal formation at birth, a family history, etc.

The market is growing at a very steady pace. Companies are opting various business strategies to capture a reasonable amount of share in the market. Product development represents the best strategy for dominating the market as surgery is the definitive treatment for intussusception market. The advent of minimally invasive treatment and diagnostic techniques such as computed tomography has changed the market landscape for to a large extent. Miniaturization of surgical instruments and development of minimal invasive treatment such as robotic laparoscopy is expected to drive the future market in the developed regions of North America and Europe. The cost of the product will be a decisive factor in the developing regions such as Asia Pacific and, especially, Africa. The growing demand for better minimally invasive surgical procedures is the greatest unmet need of the market.

The developments in the surgery segment, such as minimal invasive laparoscopy surgery, is driving the global intussusception market. The drug segment is, however, suffering from market fragmentation, which has put pressure on the price margins. The loss of patents and the rise of counterfeited drugs has also restricted the market growth. The other market constrains are high cost of surgery and complications of the surgery. Market development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to minimal invasive surgical procedures.

Key Players in the Global Intussusception Market

Some of the key players profiled in the report are Pfizer, Inc., Janssen Pharmaceuticals, Inc., Abbott, GlaxoSmithKline plc, sanofi-aventis U.S. LLC. , Novartis AG, Bayer AG, FUJIFILM Holdings Corporation, General Electric Company, Shimadzu Corporation, Carestream Health, Bristol-Myers Squibb Company, and others.

Segments of Global Intussusception Market

The global intussusception market has been segmented on the basis of type, diagnosis, treatment, and end user.

Based on the type, the market has been segmented as Ileoileal, Ileocolic, Ileo-ileo-colic, and others.

Based on the surgery, the market has been segmented as surgery, drugs, and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

Based on the diagnosis, the market has been segmented as barium enema, ultrasound, X-ray, computerized tomography (CT), and others.

Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report